Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOquin in High Risk Superficial Bladder Cancer
NCT00141531Phase 2Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Jul 2005
- Primary completion
- Dec 2009
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apaziquone in bladder cancer, sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoint: Time to progression / Duration of remission following transurethral resection of superficial bladder cancer at 18 months. Started Jul 2005; status: completed.
02
Drugs
apaziquone
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00141531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141531.